Trump Signs Executive Order To Cut Prescription Drug Prices By 30% To 80%

In a decisive move to restore fairness and accountability to America’s healthcare system, President Donald Trump announced plans to sign a sweeping executive order Monday aimed at drastically cutting the cost of prescription drugs for American families.

On Sunday evening, Trump took to Truth Social to unveil his intentions to implement a “Most Favored Nation” pricing policy—a strategy designed to align U.S. drug costs with the lowest prices paid globally. According to the President, this initiative could reduce prices “almost immediately, by 30% to 80%.”

“I will be instituting a MOST FAVORED NATION’S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World,” Trump declared.

Currently, Americans are burdened with an unsustainable $400 billion annual bill for prescription medications—often four times the price paid by consumers in other developed nations for the same products, manufactured by the same companies, in the same labs.

For decades, globalists and bureaucrats have allowed Big Pharma to rake in record profits while American citizens foot the bill. President Trump is stepping in to end that imbalance.

Though specific policy details will be outlined in the executive order, Trump framed this measure as one of his most “important and impactful” statements to date, expressing a long-standing frustration with the status quo.

“For many years the World has wondered why Prescription Drugs and Pharmaceuticals in the United States States [sic] of America were SO MUCH HIGHER IN PRICE THAN THEY WERE IN ANY OTHER NATION, SOMETIMES BEING FIVE TO TEN TIMES MORE EXPENSIVE THAN THE SAME DRUG, MANUFACTURED IN THE EXACT SAME LABORATORY OR PLANT, BY THE SAME COMPANY???” he posted. “It was always difficult to explain and very embarrassing because, in fact, there was no correct or rightful answer.”

White House Press Secretary Karoline Leavitt reinforced the administration’s commitment to delivering results for the American people. Appearing on Fox News Monday morning, Leavitt stated:

“President Trump is signing an executive order today that is going to … reduce the cost of drugs in this country by more than half at least.”

“The United States of America is less than 5% of the world’s population, yet we purchase 57% of big pharma’s profit… America is going to pay a better rate and a fairer rate to the rest of the world,” she added.

This executive order represents a revival of a key Trump initiative from his first term—one that was blocked in the courts after intense lobbying from the pharmaceutical industry. The judicial roadblocks were supported by the Biden administration, which later withdrew the plan altogether.

At the time, federal courts ruled that Medicare lacked the authority to negotiate drug prices, effectively stalling reform efforts. However, that legal hurdle was later cleared in 2022 through the Democrats' partisan Inflation Reduction Act, which authorized Medicare to negotiate the cost of a limited range of pharmaceuticals.

Trump’s original plan linked Medicare payments for certain doctor-prescribed drugs to the lowest prices paid by peer nations—countries that, unlike the U.S., use centralized government control to cap medication costs. The anticipated savings under the initial policy were estimated at $85 billion over seven years.

Critics—many aligned with the pharmaceutical lobby—are already warning that Trump’s revived effort could restrict patient access. But as experts have noted, outcomes will depend heavily on how the policy is structured and implemented.

What’s certain is that the pharmaceutical industry is gearing up for a fight. But under President Trump’s leadership, the White House appears ready to take on the entrenched interests who’ve profited from an unfair system for far too long.